Newsletter

January 2021 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 6 Percent Correct – Prev Close to 5-day Peak 83% Avg Increase – Next open to 5-day Peak 14% Other stats: Number of signals over $10/share 5 Number […]

0Comments

Sorrento Therapeutics Reports Promising Phase 1b Results of COVI-MSC in COVID ICU Patients

On January 26, Sorrento Therapeutics, Inc.  (SRNE) announced preliminary results from a Phase 1b study of COVID-MSC for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS). COVI-MSC is an infusion treatment of human allogeneic adipose-derived mesenchymal stem cells. The three patients in the study experienced no infusion-related adverse effects and […]

0Comments

December 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 24 Percent Correct – Prev Close to 5-day Peak 96% Avg Increase – Next open to 5-day Peak 12% Other stats: Number of signals over $10/share 16 Number […]

0Comments

Curis Updates Phase 1 Clinical Trial Results for Non-Hodgkin’s Lymphoma Treatment

On December 8, Curis, Inc. (CRIS) presented updated data on its Phase 1 clinical trial of CA-4948, an IRAK4 kinase inhibitor to treat patients with relapsed or refractory (R/R) non-Hodgkin’s lymphoma (NHL). The treatments was well tolerated by patients, and 6 out of 7 experienced anti-cancer activity marked by a decrease in tumor burden. As […]

0Comments

FDA Approves ORLADEYO by BioCryst for to Prevent HAE Attacks

On December 3, BioCryst Pharmaceuticals, Inc. (BCRX) announced that the FDA approved oral, once-daily ORLADEYO™ (berotralstat) to prevent hereditary angioedema (HAE) attacks in adults and pediatric patients over the age of 12. This is the first oral non-steroidal treatment option for people with HAE. In the Phase 3 clinical trial, ORLADEYO™ significantly reduced HAE attacks […]

0Comments

November 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 8% Other stats: Number of signals over $10/share 7 Number […]

0Comments

October 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: October Scorecard Number of Signals 20 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 7% Other stats: Number of signals over $10/share 14 Number […]

0Comments

September 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: September Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 83% Avg Increase – Next open to 5-day Peak 7% Other stats: Number of signals over $10/share 7 Number […]

0Comments

Spero Therapeutics Announces Positive Phase 3 Clinical Trial Results From ADAPT-PO

On August 8, Spero Therapeutics, Inc. (SPRO) announced positive topline results from its Phase 3 clinical trial. The ADAPT-PO clinical trial evaluates Spero’s oral antibiotic candidate tebipenem HBr for the treatment of complicated urinary tract (cUTI) infection and acute pyelonephritis (AP) in adults. The results showed that Spero’s oral treatment was statistically non-inferior to intravenous […]

0Comments

August 2020 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: August Scorecard Number of Signals 12 Percent Correct – Prev Close to 5-day Peak 100% Avg Increase – Next open to 5-day Peak 6% Other stats: Number of signals over $10/share 7 Number […]

0Comments